Journey Medical Co. (NASDAQ:DERM) Receives $9.88 Consensus PT from Analysts

Shares of Journey Medical Co. (NASDAQ:DERM) have been given an average recommendation of “Buy” by the five research firms that are currently covering the firm, MarketBeat Ratings reports. Four equities research analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $9.88.

A number of research analysts have weighed in on DERM shares. Industrial Alliance Securities set a $10.50 price objective on shares of Journey Medical in a report on Thursday, March 27th. Wall Street Zen lowered shares of Journey Medical from a “buy” rating to a “hold” rating in a research report on Saturday. Finally, Alliance Global Partners reiterated a “buy” rating on shares of Journey Medical in a research report on Thursday, May 15th.

Insider Activity

In related news, CEO Claude Maraoui sold 4,834 shares of the business’s stock in a transaction dated Friday, May 2nd. The shares were sold at an average price of $6.84, for a total transaction of $33,064.56. Following the transaction, the chief executive officer now directly owns 2,348,313 shares in the company, valued at approximately $16,062,460.92. The trade was a 0.21% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Company insiders own 15.03% of the company’s stock.

Hedge Funds Weigh In On Journey Medical

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Titleist Asset Management LLC increased its holdings in shares of Journey Medical by 18.3% during the 1st quarter. Titleist Asset Management LLC now owns 12,900 shares of the company’s stock worth $76,000 after buying an additional 2,000 shares during the last quarter. Cetera Investment Advisers lifted its holdings in Journey Medical by 21.8% in the fourth quarter. Cetera Investment Advisers now owns 13,839 shares of the company’s stock valued at $54,000 after acquiring an additional 2,478 shares during the last quarter. Cambridge Investment Research Advisors Inc. lifted its holdings in Journey Medical by 3.0% in the first quarter. Cambridge Investment Research Advisors Inc. now owns 338,050 shares of the company’s stock valued at $1,994,000 after acquiring an additional 9,938 shares during the last quarter. Kovitz Investment Group Partners LLC lifted its holdings in Journey Medical by 112.9% in the fourth quarter. Kovitz Investment Group Partners LLC now owns 24,710 shares of the company’s stock valued at $97,000 after acquiring an additional 13,105 shares during the last quarter. Finally, Jane Street Group LLC acquired a new position in Journey Medical in the first quarter valued at approximately $110,000. 7.25% of the stock is currently owned by institutional investors and hedge funds.

Journey Medical Stock Down 0.6%

DERM opened at $6.74 on Friday. Journey Medical has a fifty-two week low of $3.54 and a fifty-two week high of $8.25. The company has a debt-to-equity ratio of 1.81, a quick ratio of 1.03 and a current ratio of 1.38. The company has a fifty day moving average of $6.97 and a two-hundred day moving average of $5.69. The stock has a market capitalization of $157.02 million, a price-to-earnings ratio of -7.17 and a beta of 0.87.

Journey Medical (NASDAQ:DERM) last released its quarterly earnings data on Wednesday, May 14th. The company reported ($0.18) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.06. Journey Medical had a negative net margin of 31.74% and a negative return on equity of 132.10%. The company had revenue of $13.14 million during the quarter, compared to analysts’ expectations of $12.05 million. On average, research analysts expect that Journey Medical will post -1.02 earnings per share for the current year.

About Journey Medical

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.